Metformin protects against the development of fructose-induced steatosis in mice: Role of the intestinal barrier function

Laboratory Investigation

Volumn 92, Issue 7, 2012, Pages 1020-1032

  Spruss, Astrid ^a   Kanuri, Giridhar ^a   Stahl, Carolin ^a   Bischoff, Stephan C ^a   Bergheim, Ina ^a  

^a UNIVERSITY OF HOHENHEIM   (Germany)

Author keywords

endotoxin; MMPs; NAFLD; sugar; tight junction

Indexed keywords

4 HYDROXYNONENAL; ADIPONECTIN; ALANINE AMINOTRANSFERASE; COLLAGENASE 3; ENDOTOXIN; FRUCTOSE; GAMMA INTERFERON; GELATINASE B; INSULIN; INTERLEUKIN 1BETA; LEPTIN; MESSENGER RNA; METFORMIN; OCCLUDIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN ZO1; RETINOL BINDING PROTEIN 4; SCATTER FACTOR RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TOLL LIKE RECEPTOR 4; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL TRANSLOCATION; BODY WEIGHT; CALORIC INTAKE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; DUODENUM; GENE EXPRESSION; HEPATITIS; INSULIN RESISTANCE; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; KUPFFER CELL; LIPID LIVER LEVEL; LIPID STORAGE; LIPID TRANSPORT; LIVER PROTECTION; MOUSE; NEUTROPHIL COUNT; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANIMALS; DISEASE MODELS, ANIMAL; ENDOTOXINS; FATTY LIVER; FRUCTOSE; GENE EXPRESSION; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIVER; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 9; METFORMIN; MICE; MICE, INBRED C57BL; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA, MESSENGER; SIGNAL TRANSDUCTION; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TOLL-LIKE RECEPTOR 4; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84862999195     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2012.75     Document Type: Article

References (35)

1. Yang SQ, Lin HZ, Mandal AK, et al. Disrupted signaling and inhibited regeneration in obese mice with fatty livers: implications for nonalcoholic fatty liver disease pathophysiology. Hepatology 2001;34:694-706. (Pubitemid 32927993)
2. Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005;42:44-52. (Pubitemid 40911310)
3. Ouyang X, Cirillo P, Sautin Y, et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 2008;48:993-999.
4. Thuy S, Ladurner R, Volynets V, et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr 2008;138:1452-1455.
5. Ackerman Z, Oron-Herman M, Grozovski M, et al. Fructose-induced fatty liver disease: hepatic effects of blood pressure and plasma triglyceride reduction. Hypertension 2005;45:1012-1018. (Pubitemid 40628952)
6. Armutcu F, Coskun O, Gurel A, et al. Thymosin alpha 1 attenuates lipid peroxidation and improves fructose-induced steatohepatitis in rats. Clin Biochem 2005;38:540-547. (Pubitemid 40693468)
7. Bergheim I, Weber S, Vos M, et al. Antibiotics protect against fructoseinduced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol 2008;48:983-992.
8. Jurgens H, Haass W, Castaneda TR, et al. Consuming fructosesweetened beverages increases body adiposity in mice. Obes Res 2005;13:1146-1156.
9. Spruss A, Kanuri G, Wagnerberger S, et al. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 2009;50:1094-1104.
10. Duvnjak M, Tomasic V, Gomercic M, et al. Therapy of nonalcoholic fatty liver disease: current status. J Physiol Pharmacol 2009;60(Suppl 7): 57-66.
11. Garinis GA, Fruci B, Mazza A, et al. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. Int J Obes (Lond) 2010;34:1255-1264.
12. Krakoff J, Clark JM, Crandall JP, et al. Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program. Obesity (Silver Spring) 2010;18:1762-1767.
13. Nadeau KJ, Ehlers LB, Zeitler PS, et al. Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulinresistant adolescents. Pediatr Diabetes 2009;10:5-13.
14. Lin HZ, Yang SQ, Chuckaree C, et al. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000;6:998-1003.
15. Bergheim I, Guo L, Davis MA, et al. Metformin prevents alcoholinduced liver injury in the mouse: critical role of plasminogen activator inhibitor-1. Gastroenterology 2006;130:2099-2112. (Pubitemid 43816952)
16. Kanuri G, Spruss A, Wagnerberger S, et al. Role of tumor necrosis factor alpha (TNFalpha) in the onset of fructose-induced nonalcoholic fatty liver disease in mice. J Nutr Biochem 2011;22:527-534.
17. Collison KS, Saleh SM, Bakheet RH, et al. Diabetes of the liver: the link between nonalcoholic fatty liver disease and HFCS-55. Obesity (Silver Spring) 2009;17:2003-2013.
18. Spruss A, Kanuri G, Uebel K, et al. Role of the inducible nitric oxide synthase (iNOS) in the onset of fructose-induced steatosis in mice. Antioxid Redox Signal 2011;14:2121-2135.
19. Alisi A, Manco M, Devito R, et al. Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2010;50:645-649.
20. Volynets V, Spruss A, Kanuri G, et al. Protective effect of bile acids on the onset of fructose-induced hepatic steatosis in mice. J Lipid Res 2010;51:3414-3424.
21. Chen F, Ohashi N, Li W, et al. Disruptions of occludin and claudin-5 in brain endothelial cells in vitro and in brains of mice with acute liver failure. Hepatology 2009;50:1914-1923.
22. Lischper M, Beuck S, Thanabalasundaram G, et al. Metalloproteinase mediated occludin cleavage in the cerebral microcapillary endothelium under pathological conditions. Brain Res 2010;1326:114-127.
23. Spruss A, Bergheim I. Dietary fructose and intestinal barrier: potential risk factor in the pathogenesis of nonalcoholic fatty liver disease. J Nutr Biochem 2009;20:657-662.
24. Lin HZ, Yang SQ, Chuckaree C, et al. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000;6:998-1003.
25. Chen CC, Wang HJ, Shih HC, et al. Comparison of the metabolic effects of metformin and troglitazone on fructose-induced insulin resistance in male Sprague-Dawley rats. J Formos Med Assoc 2001;100: 176-180.
26. Bergheim I, Luyendyk JP, Steele C, et al. Metformin prevents endotoxin-induced liver injury after partial hepatectomy. J Pharmacol Exp Ther 2006;316:1053-1061. (Pubitemid 43345278)
27. Kanuri G, Spruss A, Wagnerberger S, et al. Fructose-induced steatosis in mice: role of plasminogen activator inhibitor-1, microsomal triglyceride transfer protein and NKT cells. Lab Invest 2011;91: 885-895.
28. Grant PJ, Stickland MH, Booth NA, et al. Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor-1 in type 2 diabetic patients. Diabet Med 1991;8:361-365.
29. Lund SS, Tarnow L, Stehouwer CD, et al. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. Eur J Endocrinol 2008;158:631-641. (Pubitemid 351639600)
30. Pandey M, Tuncman G, Hotamisligil GS, et al. Divergent roles for p55 and p75 TNF-alpha receptors in the induction of plasminogen activator inhibitor-1. Am J Pathol 2003;162:933-941. (Pubitemid 36237500)
31. Sabate JM, Jouet P, Harnois F, et al. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis. Obes Surg 2008;18:371-377.
32. Miele L, Valenza V, La TG, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009;49:1877-1887.
33. Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat dietinduced obesity and diabetes in mice. Diabetes 2008;57:1470-1481.
34. Maury E, Brichard SM, Pataky Z, et al. Effect of obesity on growth-related oncogene factor-alpha, thrombopoietin, and tissue inhibitor metalloproteinase-1 serum levels. Obesity (Silver Spring) 2010;18:1503-1509.
35. Unal R, Yao-Borengasser A, Varma V, et al. Matrix metalloproteinase-9 is increased in obese subjects and decreases in response to pioglitazone. J Clin Endocrinol Metab 2010;95:2993-3001.